ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Santanello, N.
Right arrow Articles by Barber, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Santanello, N.
Right arrow Articles by Barber, B.
Eur Respir J 1999; 14: 23-27
Copyright © ERS Journals Ltd 1999

Clinical Trial

What are minimal important changes for asthma measures in a clinical trial?

NC Santanello, J Zhang, B Seidenberg, TF Reiss, and BL Barber

In this study, the perceptions of asthmatics to change in their disease was associated with observed changes in clinical asthma measures, in order to identify the threshold where changes in clinical asthma measures are perceivable by patients. The study included 281 asthmatic patients, aged 18-63 yrs, in a randomized, placebo-controlled clinical trial of a leukotriene antagonist. Changes were related in: 1) asthma symptom scores; 2) inhaled beta-agonist use; 3) forced expiratory volume in one second (FEV1); and 4) peak expiratory flow (PEF) to a global question that queried overall change in asthma since starting the study drug. Additional analyses examined differences in the group reporting minimal improvement by treatment (active treatment versus placebo), sex and age groups. The average minimal patient perceivable improvement for each measure was: 1) -0.31 points for the symptom score on a scale of 0-6; 2) -0.81 puffs x day(-1) for inhaled beta-agonist use; 3) 0.23 L for FEV1; and 4) 18.79 L x min(-1) for PEF. In general placebo-treated patients and older patients, who reported minimal improvement, experienced less mean improvement from baseline than active-treated patients and younger patients, who reported minimal improvement. Determining the minimal patient perceivable improvement value for a measure may be helpful to interpret changes. However, interpretation should be carried out cautiously when reporting a single value as a clinically important change.


This article has been cited by other articles:


Home page
 Am. J. Respir. Crit. Care Med.Home page
H. K. Reddel, D. R. Taylor, E. D. Bateman, L.-P. Boulet, H. A. Boushey, W. W. Busse, T. B. Casale, P. Chanez, P. L. Enright, P. G. Gibson, et al.
An Official American Thoracic Society/European Respiratory Society Statement: Asthma Control and Exacerbations: Standardizing Endpoints for Clinical Asthma Trials and Clinical Practice
Am. J. Respir. Crit. Care Med., July 1, 2009; 180(1): 59 - 99.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
G. J. Rodrigo
Rapid effects of inhaled corticosteroids in acute asthma: an evidence-based evaluation.
Chest, November 1, 2006; 130(5): 1301 - 1311.
[Abstract] [Full Text] [PDF]

Home page
 ptjournalHome page
S. M Haley and M. A Fragala-Pinkham
Interpreting Change Scores of Tests and Measures Used in Physical Therapy
Physical Therapy, May 1, 2006; 86(5): 735 - 743.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
G J Rodrigo and J A Castro-Rodriguez
Anticholinergics in the treatment of children and adults with acute asthma: a systematic review with meta-analysis
Thorax, September 1, 2005; 60(9): 740 - 746.
[Abstract] [Full Text] [PDF]

Home page
 Med Decis MakingHome page
B. Barrett, D. Brown, M. Mundt, and R. Brown
Sufficiently Important Difference: Expanding the Framework of Clinical Significance
Med Decis Making, May 1, 2005; 25(3): 250 - 261.
[Abstract] [PDF]

Home page
 Proc Am Thorac SocHome page
J. F. Donohue and J. A. Ohar
Effects of Corticosteroids on Lung Function in Asthma and Chronic Obstructive Pulmonary Disease
Proceedings of the ATS, November 1, 2004; 1(3): 152 - 160.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
D. Wensley and M. Silverman
Peak Flow Monitoring for Guided Self-management in Childhood Asthma: A Randomized Controlled Trial
Am. J. Respir. Crit. Care Med., September 15, 2004; 170(6): 606 - 612.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
M Masoli, M Weatherall, S Holt, and R Beasley
Clinical dose-response relationship of fluticasone propionate in adults with asthma
Thorax, January 1, 2004; 59(1): 16 - 20.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
G. J. Rodrigo and C. Rodrigo
The Role of Anticholinergics in Acute Asthma Treatment* : An Evidence-Based Evaluation
Chest, June 1, 2002; 121(6): 1977 - 1987.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
G. H. Guyatt, D. Osoba, A. W. Wu, K. W. Wyrwich, G. R. Norman, and Clinical Significance Consensus Meeting Group
Methods to Explain the Clinical Significance of Health Status Measures
Mayo Clin. Proc., April 1, 2002; 77(4): 371 - 383.
[Abstract] [PDF]

Home page
 Eur Respir JHome page
E.D. Bateman, J. Bousquet, and G.L. Braunstein
Is overall asthma control being achieved? A hypothesis-generating study
Eur. Respir. J., April 1, 2001; 17(4): 589 - 595.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
B. Stenius-Aarniala, T. Poussa, J. Kvarnström, E.-L. Grönlund, M. Ylikahri, and P. Mustajoki
Immediate and long term effects of weight reduction in obese people with asthma: randomised controlled study
BMJ, March 25, 2000; 320(7238): 827 - 832.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the European Respiratory Society.